GlassScriptPhysician profile
Gary Reed Brouillette
NPI 1780044834
$2,328.39
in general payments reported to CMS, 2019-2025
21 companies · $277 in 2025
The $277 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $925 · 2022: $141 · 2023: $543 · 2024: $442 · 2025: $277.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,262.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,262.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $441.20 | 2021-2025 | |
| Glaxosmithkline, LLC. | $316.41 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $234.46 | 2021-2025 | Repatha, Otezla, Otezla |
| Astrazeneca Pharmaceuticals LP | $202.15 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $200.01 | 2021-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $164.03 | 2021-2023 | Xifaxan |
| Lilly USA, LLC | $133.83 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Shield Therapeutics INC | $126.64 | 2023-2024 | Accrufer |
| Mylan Specialty L.P. | $121.90 | 2021-2024 | Yupelri |
| Gilead Sciences, INC. | $79.87 | 2021 | |
| Novo Nordisk INC | $65.65 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $60.70 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $40.74 | 2023-2024 | |
| Otsuka America Pharmaceutical, INC. | $24.42 | 2021 | |
| Phathom Pharmaceuticals, INC. | $24.32 | 2024 | Voquezna |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $23.28 | 2023 | Cologuard Collection Kit |
| Eisai INC. | $17.01 | 2021 | |
| Viatris Specialty LLC | $14.48 | 2025 | Yupelri |
| Biohaven Pharmaceuticals, INC. | $13.14 | 2021 | |
| Merck Sharp & Dohme LLC | $12.17 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $11.98 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Brouillette listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.